1. Citicoline Eye Drops Protect Trabecular Meshwork Cells from Oxidative Stress Injury in a 3D In Vitro Glaucoma Model.
- Author
-
Vernazza S, Passalacqua M, Tirendi S, Marengo B, Domenicotti C, Sbardella D, Oddone F, and Bassi AM
- Subjects
- Cytidine Diphosphate Choline pharmacology, Cytokines pharmacology, Humans, Hydrogen Peroxide pharmacology, Intraocular Pressure, Ophthalmic Solutions pharmacology, Oxidative Stress, Reactive Oxygen Species pharmacology, Glaucoma drug therapy, Trabecular Meshwork
- Abstract
Intraocular pressure (IOP) is considered an important modifiable risk factor for glaucoma, which is known as the second leading cause of blindness worldwide. However, lowering the IOP is not always sufficient to preserve vision due to other non-IOP-dependent mechanisms being involved. To improve outcomes, adjunctive therapies with IOP-independent targets are required. To date, no studies have shown the effect of citicoline on the trabecular meshwork (TM), even though it is known to possess neuroprotective/enhancement properties and multifactorial mechanisms of action. Given that reactive oxygen species seem to be involved in glaucomatous cascade, in this present study, an advanced millifluidic in vitro model was used to evaluate if citicoline could exert a valid TM protection against oxidative stress. To this end, the cellular behavior, in terms of viability, apoptosis, mitochondrial state, senescence and pro-inflammatory cytokines, on 3D human TM cells, treated either with H
2 O2 alone or cotreated with citicoline, was analyzed. Our preliminary in vitro results suggest a counteracting effect of citicoline eye drops against oxidative stress on TM cells, though further studies are necessary to explore citicoline's potential as a TM-target therapy.- Published
- 2022
- Full Text
- View/download PDF